Acasti Pharma Revenue, Profits - ACST Annual Income Statement

Add to My Stocks
$0.77 $0.07 (8.33%) ACST stock closing price Sep 25, 2018 (Closing)

ACST stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Acasti Pharma stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. Like any other income statement, the ACST income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a YOY revenue decline of 0 when compared to the same period in the past. The operating expenses as shown in the Acasti Pharma profit and loss statement for 2017 total to $7.99M. This line item shows that the operating expenses has decreased compared with last year. Also check: Acasti Pharma assets and Acasti Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Apr - Mar20172016201620152015201420142013
Acasti Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)--------
Acasti Pharma Gross Profit
Research & Development Expense5.51M5.51M5.66M5.66M5.8M5.8M4.11M4.11M
Selling General & Admin Expense2.48M2.48M1.67M1.67M5.26M5.26M6.42M6.42M
Income Before Depreciation Depletion Amortization-8M-8M-7.37M-7.37M-11.03M-11.03M-10.33M-10.33M
Depreciation Depletion Amortization--------
Non Operating Income-0.02M-0.02M2.52M2.52M9.56M9.56M-0.77M-0.77M
Interest Expense--------
Acasti Pharma Pretax Income
Provision for Income Taxes-0.09M-0.09M------
Investment Gains Losses--------
Other Income--------
Income Before Extraordinaries & Disc Operations-7.99M-7.99M-4.84M-4.84M-1.47M-1.47M-11.11M-11.11M
Extraordinary Items & Discontinued Operations--------
Acasti Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS10.8M10.8M10.71M10.71M8.28M8.28M8.29M8.29M
Average Shares used to compute Basic EPS10.8M10.8M10.71M10.71M8.28M8.28M8.29M8.29M
Income Before Nonrecurring Items-7.99M-7.99M-4.85M-4.85M-1.34M-1.34M-11.61M-11.61M
Income from Nonrecurring Items--------
Acasti Pharma Earnings Per Share Basic Net
Acasti Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-0.74-0.74-0.45-0.45-0.20-0.20-1.40-1.40
Preferred Dividends Acc Pd--------
Dividends Common0.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The key things to look for in an income statement while doing Acasti Pharma stock analysis are:

  • Topline: A growing topline, as seen from the Acasti Pharma revenue chart, as isn't the case with Acasti Pharma indicates a sagging business. One needs to compare the YoY topline or sales growth of ACST stock with its peers like EVOK stock and VSAR stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: Most businesses like Acasti Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The ACST financials along with Acasti Pharma historical stock prices provide a lot of details about the firm.

Acasti Pharma Income Statement - Key Financial Ratios

Operating Margin
Net Profit Margin